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We analyzed the effect of acetylated low density lipoprotein (aLDL) incubation on tumor necrosis factor (TNF) mRNA and protein expression 
in isolated resting human monocytes in serum free DMEM. TNF mRNA expression was about one third that of PMA and was dose dependent. 
The maximum stimulatory effect on TNF mRNA was at 250 pg/ml, while 500 @g/ml induced downregulation. The maximum stimulatory effect 
occurred at 6 hours, and by 24 hours TNF mRNA expression returned to the resting state. Acetyl LDL also induced the expression of immunoreac- 
tive TNF, reaching a sevenfold maximum above control at 12 hours following a 6 hour exposure period. The results suggest hat aLDL is a potent 
stimulator of TNF expression in resting monocytes. This mechanism ay be operational in atheroma evolution. 
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1. INTRODUCTION 
Monocytes are thought to participate in athero- 
genesis, both as foam cells [1,2] and as a source of 
growth factors and cytokines [3]. One such cytokine is 
tumor necrosis factor (TNF) which can cause cell pro- 
liferation [4,5], angiogenesis [6] and cell necrosis [7]. 
We have previously detected TNF in human atheroma 
by immunohistochemistry [8] and by in situ hybridiza- 
tion [9]. Resting monocytes, however, do not express 
the TNF gene [lo]. Its expression is induced by factors 
such as phorbol esters, e.g. PMA [I 11, LPS [12] or even 
by the cell isolation process [I 11. Since LDL is a major 
lipid that accumulates in MO [13] and SMC [14] of the 
atherosclerotic lesion, and is also a general cellular ac- 
tivator [ 151, we hypothesized that LDL may trigger 
TNF production in MO. Consequently, the goals of this 
study were (i) to determine if LDL activates MO to ex- 
press TNF, and (ii) to determine the dose dependence 
and time kinetics of MO activation. 
2. MATERIALS AND METHODS 
2.1. Reagents and cells 
LDL, HDL, PMA, Histopaque, PMX B, Na acetate, and 
lipoprotein-deficient FCS were obtained from Sigma; RPM1 1640, 
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DMEM and tissue culture dishes from Gibco; tissue culture chambers 
from LAB-TEK; TNF ELISA kit (Biokine) from T Cell Sciences; anti 
human rTNF alpha monoclonal antibody was a gift of Dr M. Narachi 
(Amgen); Limulus amebocyte lysate endotoxin assay (Pyrotell) from 
Associates of Cape Cod; Ilford K5 nuclear emulsion from Ilford. 
Monocytes were obtained from the buffy coat of healthy human 
donors with normal lipoprotein profiles. The cells were separated on 
Histopaque discontinuous gradient [16]. Cells, at a concentration of 
0.5-2.8 x log/dish, were incubated in RPM1 1640 supplemented with 
10% lipoprotein-deficient FCS, and were allowed to attach for 18 h 
in 35 mm plastic dishes in 5% COz at 37°C. Cells were >93% viable 
(Trypan blue exclusion) and were proven to be > 90% monocytes by 
non-specific esterase staining. At the end of the attachment period the 
medium was replaced with serum free DMEM for the rest of the ex- 
periments. As monocyte-derived macrophages express only few native 
LDL receptors and internalize only minimal ipoprotein [17], we used 
chemically modified (acetylated) LDL which is taken up more rapidly 
by way of distinct, scavenger receptors [17,18]. Cells were incubated 
with either DMEM alone (control), with PMA (positive control) or 
with aLDL (experimental group). LDL was acetylated by saturated 
sodium acetate and the success of acetylation was verified by the 
typical enhanced electrophoretic mobility [18]. We also incubated MO 
in some experiments with equivalent concentration of native LDL and 
HDL. 
2.2. RNA extraction and Northern analysis 
Total cellular RNA was isolated by an acid guanidinium thio- 
cyanate-phenol-chloroform extraction technique [ 191 and was 
analyzed by Northern blot [20]. The cDNA probe was a human 800 
bp EcoRI cDNA fragment from Genentech, San Francisco, CA [21]. 
Autoradiograms were read on a semiautomatic densitometer (E-C 
Apparatus Corporation). 
2.3. Histological techniques 
MO were fixed in the culturing chamnbers by 10% neutral buffered 
formalin. For immunohistochemical staining antihuman rTNA alpha 
monoclonal antibody and peroxidase labelled double antibody techni- 
que was used as described earlier [S]. In situ hybridization on freshly 
fixed MO was carried out with the TNF cDNA probe as described 
earlier [9]. TNF concentration in the supernatant was measured with 
a commercial ELISA kit [22] which showed good correlation with L 
929 Bioassay. 
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2.4. Screening for endotoxin contamination 3.2. Kinetics of TNF mRNA accumulation 
All components of the incubating system were screened for en- 
dotoxin by chromogenic limulus amoebocyte lysate assay. We used 
only materials with endotoxin levels less than 40 pg/ml in these ex- 
periments. In some instances we ran parallel experiments with or 
without LPS antagonist PMX B (10 rg/ml) [l l] and compared the 
results. 
Northern blot analysis revealed induction of TNF 
mRNA expression in monocytes incubated with both 
PMA and aLDL. The aLDL induced signal was about 
one third of that induced by PMA (Fig. 2 and Table I). 
Acetyl LDL induction of TNF mRNA expression was 
dose dependent: peak level was achieved at 250,ug/ml 
aLDL concentration, while at 500 /g/ml concentration 
the expression of TNF mRNA significantly decreased 
(Fig. 3 and Table I). When MO were incubated con- 
tinuously with 250pg/ml aLDL, the peak level of TNF 
mRNA expression occurred at 6 h and returned to 
baseline within 24 h (Fig. 4 and Table I). 
3. RESULTS 
3.1. Morphological finding 
Oil red 0 staining showed heavy perinuclear lipid ac- 
cumulation in monocytes exposed to aLDL, but not in 
control cells (Fig. la,b). In situ hybridization revealed 
accumulation of silver grains exclusively over the 
monocytes indicating TNF mRNA expression (Fig. lc, 
d,e). Immunohistochemical staining revealed diffuse 
cytoplasmic TNF positivity (Fig. lf). 
3.3. Secretion of TNF by aLDL incubated monocytes 
The immunoreactive TNF concentration in the in- 
cubation media was 3-fold greater in the MO incubated 
with aLDL than in those incubated with DMEm alone 
after 6 h incubation. Native LDL and HDL did not in- 
duce TNF expression. The peak TNF concentration 
(7-fold greater than the control level) was reached at 6 
h after removal of aLDL. After 24 h TNF was undetec- 
table in the supernatant of both the treated and the con- 
trol MO (Fig. 5). 
4. DISCUSSION 
In this study we report for the first time that 
acetylated LDL incubation induces the expression of 
TNF mRNA in human MO. The increased mRNA ex- 
pression was accompanied by production of immuno- 
reactive TNF. The strength of TNF mRNA induction 
- 
Fig. 1. Panel a and b: Oil red 0 staining of human blood MO. 
Methylene blue nuclear staining. Panel a: one of the control MO. They 
were allowed to attach in RPM1 1640 medium containing 10% 
lipoprotein deficient FCS for 18 h, then they were incubated in serum- 
free DMEM without aLDL. There is no cytoplasmic staining with Oil 
red 0. Panel b: one of the aLDL incubated monocytes tained by oil 
red 0. Following the attachment period they were incubated with 250 
pg/ml aLDL for 6 h. There is intensive cytoplasmic staining with Oil 
red 0 indicating massive lipid uptake. Panel c: immunohistochemical 
staining for TNF. MO incubated with 250 pg/ml aLDL for 6 h were 
stained using monoclonal antibody against rhTNF. LY and peroxidase 
labelled double antibody technique. Cells show positive cytoplasmic 
brown staining. Panels d-f: in situ hybridization for TNF mRNA. 
Nuclear staining with hematoxylin. Control MO were unstimulated 
(Panel e). MO were stimulated with 50 ng/ml PMA for 4 h (Panel d) 
or were incubated with 250pg/ml of aLDL for 6 h (Panel f). Cells 
were fixed in the tissue culture chambers with 10% neutral buffered 
formalin, then were digested by proteinase K for 15 min at 37°C and 
treated in acetic anhydride for 10 min at room temperature. We prob- 
ed the cells with a human TNF cDNA probe (in 50% formamide, 2% 
dextrane sulphated, ds thymus DNA and EDTA) labelled with 2 
Ci/ng probe [cr-‘*P]dCTP for 18 h at 37°C in a humidity chamber. 
Slides were washed with high stringency (max at 55°C in 0.1 SSC for 
2 x 15 min). Slides were coated with Ilford K5D nuclear emulsion and 
were exposed for 3 days. Control MO reveal only background level ac- 
tivity. After PMA and aLDL incubation there was an increase in TNF 
mRNA accumulation. 
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was one-third of that of PMA, one of the strongest 
known inducers of TNF gene expression [111. 
The mechanism by which aLDL stimulates TNF ex- 
pression is not clear. TNF production in monocytes is a 
complex process that involves both transcriptional and 
post-transcriptional control [lo]. PMA, a tumor pro- 
moter seems to induce TNF production in monocytes 
through direct protein kinase C activation [23]. Acetyl 
LDL has recently been shown to be a general cellular ac- 
tivator which acts by increasing membrane receptor 
mediated phosphatidylinositol turnover [ 15,241 which 
in turn secondarily translocates (activates) protein 
kinase C [25]. Thus, aLDL could act earlier in the se- 
quence of activation, while inducing TNF expression 
through a mechanism similar to PMA. 
TNF 
PMA C aLDL 
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Fig. 2. Northern analysis of TNF mRNA of human MO. Freshly 
prepared MO were incubated in RPM1 1640 and 10% lipoprotein defi- 
cient FCS and allowed to attach for 18 h. The attached monocytes 
were then incubated either in serum-free DMEM alone (C) or in that 
containing 50 ng/ml PMA or 250 fig/ml aLDL. Total RNA was ex- 
tracted and 20 pg RNA were run on each lane of an agarose for- 
maldehyde gel, transferred to a nylon membrane, and hybridized with 
radiolabelled TNF cDNA probe. In the control MO incubated in 
DMEM alone there was no TNF mRNA expression while both PMA 
and aLDL induced TNF mRNA expression. Alpha actin probing 
showed no induction and indicates similar amounts of RNA on each 
Fig. 3. Dose-dependence of the induction of TNF mRNA by aLDL. 
After the attachment period (see Fig. 2) MO were incubated with the 
indicated concentrations of aLDL. Total RNA was extracted and 
probed as above. Maximal induction occurred at 250 @g/ml aLDL 
concentration, while at 500 pg/ml TNF mRNA seemed to be down- 
lane. regulated. 
Table I 
Effect of aLDL on TNF mRNA. The values shown are the integrals 
of peaks determined by scanning autoradiograms in the linear range 
of the film with a semi-automatic densitometer. The amount of 
RNA/lane, labelling and exposure conditions were uniform within 
each group of experiments 
TNF ACTIN 
PMA 317,250 441,510 
C 5,450 403,530 
aLDL 86,430 451,075 
50 101,340 
100 318,610 
250 273,910 
500 36,818 
8 518,880 
6 997,110 
12 790,790 
18 627,700 
24 2,951 
36 14,210 
48 10,902 
Acetyl LDL is taken up by scavenger eceptors [ 171. 
Since there was no other source of lipid in the serum- 
free medium, the heavy cytoplasmic lipid accumulation 
demonstrated by Oil red 0 stain suggests that the ac- 
cumulated lipid was aLDL, although we did not 
specifically established the identity of the intracellular 
aLDL ( pg/ml) 
50 100 250 500 
TNF 
* nlw_ * _~ 
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Fig. 4. Time kinetics of the induction of TNF mRNA by aLDL in- 
cubation in human MO. After the attachment period MO were in- 
cubated with 250 pg/ml aLDL. Following the indicated incubation 
periods total RNA was extracted and hybridized to TNF cDNA pro- 
bes. The peak level of TNF mRNA expression was reached at 6 h of 
stimulation with aLDL; by 24 h TNF mRNA expression decreased to 
the steady state level. 
lipid. Minimal cytoplasmic lipid accumulation was 
detected by Oil red 0 after incubation with native LDL 
and HDL. These lipids did not induce TNF expression 
although they can activate MO, e.g. increasing ,& 
glucuronidase secretion [26]. Thus, our data suggest 
that intracellular aLDL accumulation may cause TNF 
gene expression, although activation of the membrane- 
localized phosphatidylinositol system during the entry 
of aLDL is also a possibility. Presence of oxidatively 
modified LDL [27] and the functional integrity (in- 
cluding TNF production) of lipid-loaded macrophages 
[28] have recently been demonstrated. 
The time course of TNF mRNA accumulation and 
protein secretion was consistent with transcriptional 
and translational activation. In spite of the continuous 
presence of aLDL in the media, the MO TNF mRNA ex- 
pression was transient, returning to the resting level in 
24 h. To study the time course of TNF protein produc- 
tion, we removed the aLDL after 6 h of incubation and 
actually measured the production and decay of TNF in 
6 h periods. TNF production peaked 6 h after removal, 
i.e., 12 h after initial exposure and became undetectable 
at 24 h. There was also transient TNF production 
detected in the control MO. This was attributed to the 
transient activation of MO during the isolation pro- 
cedure. 
Both LDL [ 131 and MO [ 121 are involved in 
atherogenesis. Our study suggests one potentially im- 
portant link between the two, through expression of 
TNF. The role of TNF and other cytokines in athero- 
genesis has not been established. Nevertheless, only 
atherosclerotic human arteries express TNF, and the 
amount of immunoreactive TNF increases as the 
atheroma becomes complicated [B]. Thus, it is possible 
that LDL uptake initiates production of growth factors 
and cytokines such as TNF and IL-l that are mitogenic 
[4,5], angiogenic [6] and cytotoxic [7], leading to evolu- 
tion of the atheroma from the fatty streaks through the 
proliferative lesion to vascularized, necrotic unstable 
atheroma. 
- rLDL t25Opg/mlj 
- - - - control 
8 1 
0 6 12 18 24 30 36 42 48 hours 
Fig. 5. Time kinetics of TNF protein production by human MO measured by ELBA. After the attachment period MO were incubated either in 
serum-free DMEM alone or in serum-free DMEM containing 250pg/ml aLDL for 6 h. The first ELBA was performed at the end of this period 
(0 h). Then the medium was changed to fresh serum-free DMEM in both groups at the periods indicated on the abscissa. Data represent TNF pro- 
duction and decay by 1000 MO within the indicated time intervals after a single 6 h stimulation with aLDL. Data shown are mean+SEM of 
duplicates for 3 experiments. TNF production was higher at the end of the incubation with aLDL than with medium alone, and revealed further 
increase during the next 6 h period in spite of aLDL removal. Afterwards there was a sharp decrease in TNF production, such that by 24 h TNF 
was not detectable. In the control group there was a small and continuously decreasing TNF production, 
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